Our Targeted Vaccines

Biologically Targeted Vaccines for Chikungunya and Zika

Improved vaccine efficacy based upon understanding basic biology of active immunization. Central immunomodulatory dendritic cell (DC) critical to elicitation of effective immunization. Based on this recognition, effective “loading” of DCs is the key step in vaccine efficacy.

Adenovirus-Based Vaccine Vectors

Adenovirus vectors (Ad) provide technical means for loading of DCs for vaccination. Adenovirus is a double strand DNA virus with a naked capsid coat. Remarkable ability to deliver genes in vivo has led to their application for gene therapy, virotherapy, and vaccine applications. Ease of manipulation and compatibility with up-scaling has made feasible human use applications

Chikungunya and Zika Vaccines

Animal Models

Michael Diamond at Washington University School of medicine has developed and validated rodent models of vaccination against alphavirus. Model of Chikungunya transmission of highest relevance for the major human disease context. Michael Diamond serves as advisor to Precision Virologics.

Dendritic Cell Targeted Adenovirus

Proven utility of adenovirus vaccines for alphavirus vaccination validates our approach. Proprietary vector targeting allows selective transduction of key immunoregulatory dendritic cells. Dendritic cells targeting allows for dramatic enhanced vaccine potency predicating optimized utility for CHIK and Zika.

Rapid Translation Capacity

St. Louis University operates NIH supported Vaccine Treatment Unit (VTU) for human testing vaccine development. SLU VTU one of first site outside NIH to test CHIK and Zika vaccines in humans. SLU VTU senior scientists Dan Hoft and Sarah George serve as advisors to Precision Virologics.

Adenovirus Agents For Vaccination

Clinical studies have defined key threshold level of serum AAT to realize effective lung protection. AAV vector strategies evaluated to date have not achieved corrective levels of serum AAT. Adenovirus achieves unparalleled in vivo gene delivery to accomplish effective AAT levels.

Precision Virologics Vaccine Vectors Are Designed To Enhance Loading Of Dendritic Cells

Porcine knob 4 recognizes gelectins expressed on DC surface. Allows enhanced infectivity of DCs.

Camelid antibodies (sdAb) with DC specifically recognize unique DC cell surface markers. Allows enhanced and specific infectivity of DCs.

Promising Results In Animal Models And Stringent Human Substrate Systems

Tropism modification of Ad allows enhanced infectivity for DC targeting. [1]

Enhanced infectivity confirmed in stringent human “skin plug” assay predictive of vector capacity of human clinical trials context. [2]

Enhanced infectivity allows improved vaccine outcomes in murine model of melanoma immunotherapy. [3] [4]

Technology Validation

Unique Technical Capacities

Targeting DCs and Functional DC Subsets

Dendritic cells essential for orchestrating effective active immunization. Newly identified DC functional subsets provide key cellular targets for optimized DC targeting. Camelid technology provides flexible platform to target DCs via subset-specific markers – CLEC9A(+), etc.

Precision Virologics – Intellectual Property

Porcine knob xenotype chimeric Ad vector for dendritic cell infection.

 

  • US Patent 9,267,153
  • Assignee: Washington University
  • Inventors: David T. Curiel

Camelid antibody species for retargeting adenoviral vectors (Ad)

  • US Patent Application 61/981,462
  • Assignee: Washington University
  • Inventors: David T. Curiel, Sergey Kaliberov